1
|
Tsesmelis M, Büttner UFG, Gerstenlauer M, Manfras U, Tsesmelis K, Du Z, Sperb N, Weissinger SE, Möller P, Barth TFE, Maier HJ, Chan LK, Wirth T. NEMO/NF-κB signaling functions as a double-edged sword in PanIN formation versus progression to pancreatic cancer. Mol Cancer 2024; 23:103. [PMID: 38755681 PMCID: PMC11097402 DOI: 10.1186/s12943-024-01989-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Accepted: 03/31/2024] [Indexed: 05/18/2024] Open
Abstract
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is marked by a dismal survival rate, lacking effective therapeutics due to its aggressive growth, late-stage diagnosis, and chemotherapy resistance. Despite debates on NF-κB targeting for PDAC treatment, no successful approach has emerged. METHODS To elucidate the role of NF-κB, we ablated NF-κB essential modulator (NEMO), critical for conventional NF-κB signaling, in the pancreata of mice that develop precancerous lesions (KC mouse model). Secretagogue-induced pancreatitis by cerulein injections was utilized to promote inflammation and accelerate PDAC development. RESULTS NEMO deletion reduced fibrosis and inflammation in young KC mice, resulting in fewer pancreatic intraepithelial neoplasias (PanINs) at later stages. Paradoxically, however, NEMO deletion accelerated the progression of these fewer PanINs to PDAC and reduced median lifespan. Further, analysis of tissue microarrays from human PDAC sections highlighted the correlation between reduced NEMO expression in neoplastic cells and poorer prognosis, supporting our observation in mice. Mechanistically, NEMO deletion impeded oncogene-induced senescence (OIS), which is normally active in low-grade PanINs. This blockage resulted in fewer senescence-associated secretory phenotype (SASP) factors, reducing inflammation. However, blocked OIS fostered replication stress and DNA damage accumulation which accelerated PanIN progression to PDAC. Finally, treatment with the DNA damage-inducing reagent etoposide resulted in elevated cell death in NEMO-ablated PDAC cells compared to their NEMO-competent counterparts, indicative of a synthetic lethality paradigm. CONCLUSIONS NEMO exhibited both oncogenic and tumor-suppressive properties during PDAC development. Caution is suggested in therapeutic interventions targeting NF-κB, which may be detrimental during PanIN progression but beneficial post-PDAC development.
Collapse
Affiliation(s)
- Miltiadis Tsesmelis
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
| | - Ulrike F G Büttner
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
| | - Melanie Gerstenlauer
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
| | - Uta Manfras
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
| | - Konstantinos Tsesmelis
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
| | - Ziwei Du
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
| | - Nadine Sperb
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
| | | | - Peter Möller
- Institute of Pathology, University of Ulm, 89081, Ulm, Baden-Württemberg, Germany
| | - Thomas F E Barth
- Institute of Pathology, University of Ulm, 89081, Ulm, Baden-Württemberg, Germany
| | - Harald J Maier
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany
- Novartis Pharma, 4056, Basel, AG, Switzerland
| | - Lap Kwan Chan
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany.
- Department of Pathology and Molecular Pathology, University Hospital of Zurich, 8091, Zurich, Switzerland.
- Institute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
| | - Thomas Wirth
- Institute of Physiological Chemistry, University of Ulm, Meyerhofstrasse, 89081, Ulm, Baden-Württemberg, Germany.
| |
Collapse
|
2
|
Grasedieck S, Cabantog A, MacPhee L, Im J, Ruess C, Demir B, Sperb N, Rücker FG, Döhner K, Herold T, Pollack JR, Bullinger L, Rouhi A, Kuchenbauer F. The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements. Haematologica 2021; 107. [PMID: 34854277 PMCID: PMC9335095 DOI: 10.3324/haematol.2020.276048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Aberrant expression of Ecotropic Viral Integration Site 1 (EVI1) is a hallmark of acute myeloid leukemia (AML) with inv(3) or t(3;3), which is a disease subtype with especially poor outcome. In studying transcriptomes from AML patients with chromosome 3q rearrangements, we identified a significant upregulation of the Nuclear Receptor Interacting Protein 1 (NRIP1) as well as its adjacent non-coding RNA LOC101927745. Utilizing transcriptomic and epigenomic data from over 900 primary samples from patients as well as genetic and transcriptional engineering approaches, we have identified several mechanisms that can lead to upregulation of NRIP1 in AML. We hypothesize that the LOC101927745 transcription start site harbors a context-dependent enhancer that is bound by EVI1, causing upregulation of NRIP1 in AML with chromosome 3 abnormalities. Furthermore, we showed that NRIP1 knockdown negatively affects the proliferation and survival of 3qrearranged AML cells and increases their sensitivity to all-trans retinoic acid, suggesting that NRIP1 is relevant for the pathogenesis of inv(3)/t(3;3) AML and could serve as a novel therapeutic target in myeloid malignancies with 3q abnormalities.
Collapse
Affiliation(s)
- Sarah Grasedieck
- University of British Columbia, Department of Microbiology & Immunology, Vancouver, British Columbia, Canada
| | - Ariene Cabantog
- Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Liam MacPhee
- Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Junbum Im
- Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Christoph Ruess
- Ulm University Hospital, Department of Internal Medicine III, Ulm, Germany
| | - Burcu Demir
- Ulm University Hospital, Department of Internal Medicine III, Ulm, Germany
| | - Nadine Sperb
- Ulm University Hospital, Department of Internal Medicine III, Ulm, Germany
| | - Frank G. Rücker
- Ulm University Hospital, Department of Internal Medicine III, Ulm, Germany
| | - Konstanze Döhner
- Ulm University Hospital, Department of Internal Medicine III, Ulm, Germany
| | - Tobias Herold
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - Jonathan R. Pollack
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Lars Bullinger
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany
| | - Arefeh Rouhi
- Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada,AR and FK contributed equally as co-senior authors
| | - Florian Kuchenbauer
- Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada,AR and FK contributed equally as co-senior authors
| |
Collapse
|
3
|
Grasedieck S, Cabantog A, MacPhee L, Im J, Ruess C, Demir B, Sperb N, Rücker FG, Döhner K, Herold T, Pollack JR, Bullinger L, Rouhi A, Kuchenbauer F. The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements. Haematologica 2021; 107:1758-1772. [PMID: 34854277 DOI: 10.3324/haematol.2021.276048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Indexed: 11/09/2022] Open
Abstract
Aberrant expression of Ecotropic Viral Integration Site 1 (EVI1) is a hallmark of acute myeloid leukemia (AML) with inv(3) or t(3;3), which is a disease subtype with especially poor outcome. In studying transcriptomes from AML patients with chromosome 3q rearrangements, we identified a significant upregulation of the Nuclear Receptor Interacting Protein 1 (NRIP1) as well as its adjacent non-coding RNA LOC101927745. Utilizing transcriptomic and epigenomic data from over 900 primary patient samples as well as genetic and transcriptional engineering approaches, we have identified several mechanisms that can lead to upregulation of NRIP1 in AML. We hypothesize that the LOC101927745 transcription start site harbors a context-dependent enhancer that is bound by EVI1, causing upregulation of NRIP1 in AML with chr3 abnormalities. Furthermore, we show that NRIP1 knockdown negatively affects the proliferation and survival of 3q-rearranged AML cells and increases their sensitivity towards ATRA, suggesting that NRIP1 is relevant for the pathogenesis of inv(3)/t(3;3) AML and could serve as a novel therapeutic target in myeloid malignancies with 3q abnormalities.
Collapse
Affiliation(s)
- Sarah Grasedieck
- University of British Columbia, Dept. of Microbiology and Immunology, MSL Building, 2125 East Mall Vancouver, BC.
| | - Ariene Cabantog
- Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC
| | - Liam MacPhee
- Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC
| | - Junbum Im
- Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC
| | - Christoph Ruess
- Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm
| | - Burcu Demir
- Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm
| | - Nadine Sperb
- Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm
| | - Frank G Rücker
- Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm
| | - Konstanze Döhner
- Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm
| | - Tobias Herold
- Department of Medicine III, University Hospital, LMU Munich, Marchioninistr. 15, Munich
| | - Jonathan R Pollack
- Department of Pathology, Stanford University School of Medicine, Stanford, California
| | - Lars Bullinger
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin
| | - Arefeh Rouhi
- Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC
| | - Florian Kuchenbauer
- Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC.
| |
Collapse
|
4
|
Tsesmelis M, Tiwary K, Steiger K, Sperb N, Gerstenlauer M, Manfras U, Maier HJ, Hermann PC, Chan LK, Wirth T. Deletion of NEMO Inhibits EMT and Reduces Metastasis in KPC Mice. Cancers (Basel) 2021; 13:4541. [PMID: 34572768 PMCID: PMC8471477 DOI: 10.3390/cancers13184541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 09/04/2021] [Accepted: 09/08/2021] [Indexed: 11/23/2022] Open
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a largely incurable cancer type. Its high mortality is attributed to the lack of efficient biomarkers for early detection combined with its high metastatic properties. The aim of our study was to investigate the role of NF-κB signaling in the development and metastasis of PDAC. We used the well-established KPC mouse model, and, through genetic manipulation, we deleted NF-κB essential modulator (NEMO) in the pancreata of KPC mice. Interestingly, NEMO deletion altered the differentiation status of the primary tumor but did not significantly affect its development. However, in the absence of NEMO, the median survival of the mice was prolonged by 13.5 days (16%). In addition, examination of the liver demonstrated that, whereas KPC mice occasionally developed liver macro-metastasis, NEMO deletion completely abrogated this outcome. Further analysis of the tumor revealed that the expression of epithelial-mesenchymal transition (EMT) transcription factors was diminished in the absence of NEMO. Conclusively, our study provides evidence that NF-κB is dispensable for the progression of high-grade PanINs towards PDAC. In contrast, NF-κB signaling is essential for the development of metastasis by regulating the gene expression program of EMT.
Collapse
Affiliation(s)
- Miltiadis Tsesmelis
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (M.T.); (N.S.); (M.G.); (U.M.); (H.J.M.)
| | - Kanishka Tiwary
- Department of Internal Medicine I, University of Ulm, 89081 Ulm, Germany; (K.T.); (P.C.H.)
| | - Katja Steiger
- Department of Pathology, School of Medicine, Technical University of Munich, 81675 Munich, Germany;
| | - Nadine Sperb
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (M.T.); (N.S.); (M.G.); (U.M.); (H.J.M.)
| | - Melanie Gerstenlauer
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (M.T.); (N.S.); (M.G.); (U.M.); (H.J.M.)
| | - Uta Manfras
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (M.T.); (N.S.); (M.G.); (U.M.); (H.J.M.)
| | - Harald J. Maier
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (M.T.); (N.S.); (M.G.); (U.M.); (H.J.M.)
- Novartis Pharma AG, 4056 Basel, Switzerland
| | - Patrick C. Hermann
- Department of Internal Medicine I, University of Ulm, 89081 Ulm, Germany; (K.T.); (P.C.H.)
| | - Lap Kwan Chan
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (M.T.); (N.S.); (M.G.); (U.M.); (H.J.M.)
- Institute of Molecular Cancer Research, University of Zurich, 8057 Zurich, Switzerland
- Department of Pathology and Molecular Pathology, University Hospital of Zurich, 8091 Zurich, Switzerland
| | - Thomas Wirth
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (M.T.); (N.S.); (M.G.); (U.M.); (H.J.M.)
| |
Collapse
|
5
|
Sperb N, Tsesmelis M, Wirth T. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020; 21:E5486. [PMID: 32752017 PMCID: PMC7432853 DOI: 10.3390/ijms21155486] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 07/22/2020] [Accepted: 07/29/2020] [Indexed: 12/14/2022] Open
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer. The poor prognosis calls for a more detailed understanding of disease biology in order to pave the way for the development of effective therapies. Typically, the pancreatic tumor is composed of a minority of malignant cells within an excessive tumor microenvironment (TME) consisting of extracellular matrix (ECM), fibroblasts, immune cells, and endothelial cells. Research conducted in recent years has particularly focused on cancer-associated fibroblasts (CAFs) which represent the most prominent cellular component of the desmoplastic stroma. Here, we review the complex crosstalk between CAFs, tumor cells, and other components of the TME, and illustrate how these interactions drive disease progression. We also discuss the emerging field of CAF heterogeneity, their tumor-supportive versus tumor-suppressive capacity, and the consequences for designing stroma-targeted therapies in the future.
Collapse
Affiliation(s)
| | | | - Thomas Wirth
- Institute of Physiological Chemistry, University of Ulm, 89081 Ulm, Germany; (N.S.); (M.T.)
| |
Collapse
|
6
|
Schneider E, Pochert N, Ruess C, MacPhee L, Escano L, Miller C, Krowiorz K, Delsing Malmberg E, Heravi-Moussavi A, Lorzadeh A, Ashouri A, Grasedieck S, Sperb N, Kumar Kopparapu P, Iben S, Staffas A, Xiang P, Rösler R, Kanduri M, Larsson E, Fogelstrand L, Döhner H, Döhner K, Wiese S, Hirst M, Keith Humphries R, Palmqvist L, Kuchenbauer F, Rouhi A. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells. Leukemia 2019; 34:1253-1265. [DOI: 10.1038/s41375-019-0651-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 10/09/2019] [Accepted: 11/13/2019] [Indexed: 12/31/2022]
|
7
|
Grasedieck S, Mulaw M, Sperb N, Wessinger K, Rouhi A, Bommer M, Bromberg JEC, Otto M, Tumani H, von Arnim CAF, Mertens D, Kuchenbauer F. Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. Neuropathol Appl Neurobiol 2018; 45:318-323. [PMID: 29679382 DOI: 10.1111/nan.12491] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Sarah Grasedieck
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Medhanie Mulaw
- Institute of Experimental Cancer Research, Ulm University, Ulm, Germany
| | - Nadine Sperb
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | | | - Arefeh Rouhi
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - Martin Bommer
- Department of Hematology, Oncology, Palliative Care and Infectious Diseases, Alb-Fils-Kliniken, Göppingen, Germany
| | | | - Markus Otto
- Department of Neurology, Ulm University, Ulm, Germany
| | | | | | - Daniel Mertens
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.,DKFZ, Mechanisms of Leukemogenesis, Heidelberg, Germany
| | | |
Collapse
|